Maria E. Arcila
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Oncology top 0.1%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
Papers in
-
- Lung Cancer Treatments and Mutations 114
- Oncology 107
- Lung Cancer Research Studies 32
- Colorectal Cancer Treatments and Studies 24
- HER2/EGFR in Cancer Research 19
- Co-authors
- Marc Ladanyi (115 shared papers)Mark G. Kris (79 shared papers)Gregory J. Riely (52 shared papers)Vincent A. Miller (14 shared papers)William Pao (12 shared papers)Maureen F. Zakowski (13 shared papers)Camelia S. Sima (12 shared papers)Natasha Rekhtman (30 shared papers)
- Journals
- Journal of Clinical Oncology (55 papers)Clinical Cancer Research (23 papers)Journal of Thoracic Oncology (17 papers)Blood (16 papers)Journal of Molecular Diagnostics (14 papers)
- Partner nations
- United StatesCanadaJapan
In The Last Decade
Maria E. Arcila
242 papers receiving 15.5k citations
Maria E. Arcila's Hit Papers
Peers
Comparison fields: 5 of 122
- Pulmonary and Respiratory Medicine 10.6k
- Oncology 8.7k
- Cancer Research 4.7k
- Pathology and Forensic Medicine 1.8k
- Genetics 927
Countries citing papers authored by Maria E. Arcila
This map shows the geographic impact of Maria E. Arcila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria E. Arcila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria E. Arcila more than expected).
Fields of papers citing papers by Maria E. Arcila
This network shows the impact of papers produced by Maria E. Arcila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria E. Arcila. The network helps show where Maria E. Arcila may publish in the future.
Co-authors
The 25 scholars most cited alongside Maria E. Arcila, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 253 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers Hit paper breakdown → | 2013 | 1893 |
| 2 | HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation Hit paper breakdown → | 2012 | 555 |
| 3 | Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes Hit paper breakdown → | 2017 | 521 |
| 4 | Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations Hit paper breakdown → | 2011 | 503 |
| 5 | Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation Hit paper breakdown → | 2010 | 485 |
| 6 | Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay Hit paper breakdown → | 2011 | 476 |
| 7 | ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer Hit paper breakdown → | 2013 | 460 |
| 8 | Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels Hit paper breakdown → | 2017 | 451 |
| 9 | Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 ( HER2 ) Tyrosine Kinase Mutations in Lung Adenocarcinomas Hit paper breakdown → | 2012 | 366 |
| 10 | EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics Hit paper breakdown → | 2013 | 348 |
| 11 | Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions Hit paper breakdown → | 2017 | 331 |
| 12 | Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial Hit paper breakdown → | 2016 | 327 |
| 13 | 2017 | 317 | |
| 14 | 2011 | 299 | |
| 15 | 2012 | 289 | |
| 16 | High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden Hit paper breakdown → | 2019 | 289 |
| 17 | 2019 | 257 | |
| 18 | 2018 | 230 | |
| 19 | 2015 | 221 | |
| 20 | 2015 | 212 |
About Maria E. Arcila
Maria E. Arcila is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Pathology and Forensic Medicine, having authored 253 papers that have together received 15.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (114 papers), Cancer Genomics and Diagnostics (97 papers), Lung Cancer Research Studies (32 papers), Acute Myeloid Leukemia Research (26 papers), Colorectal Cancer Treatments and Studies (24 papers), Lymphoma Diagnosis and Treatment (21 papers), HER2/EGFR in Cancer Research (19 papers) and Genetic factors in colorectal cancer (15 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (10.6k citations), Oncology (8.7k citations), Cancer Research (4.7k citations), Pathology and Forensic Medicine (1.8k citations) and Genetics (927 citations). Maria E. Arcila has collaborated with scholars based in United States, Canada and Japan. Frequent co-authors include Marc Ladanyi, Mark G. Kris, Gregory J. Riely, Vincent A. Miller, William Pao, Maureen F. Zakowski, Camelia S. Sima, Natasha Rekhtman, Helena A. Yu and Khédoudja Nafa. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Journal of Thoracic Oncology, Blood and Journal of Molecular Diagnostics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.